Oncimmune’s CEO Martin Gouldstone, speaks to Paul Hill at Vox Markets and discusses what Oncimmune does, the significance of the recently signed $1.5m with a top 10 Pharma partner as well as the sector’s demand for autoantibody profiling services overall.
Watch the whole interview below: